Literature DB >> 24952395

The PLAU P141L single nucleotide polymorphism is associated with collateral circulation in patients with coronary artery disease.

Joan Duran1, Pilar Sánchez-Olavarría2, Marina Mola3, Víctor Götzens1, Julio Carballo4, Eva Martín-Pelegrina4, Màrius Petit4, Bruno García Del Blanco5, David García-Dorado5, Josep M de Anta6.   

Abstract

INTRODUCTION AND
OBJECTIVES: Urokinase-type plasminogen activator, which is encoded by the PLAU gene, plays a prominent role during collateral arterial growth. We investigated whether the PLAU P141L (C > T) polymorphism, which causes a mutation in the kringle domain of the protein, is associated with coronary collateral circulation in a cohort of 676 patients with coronary artery disease.
METHODS: The polymorphism was genotyped in blood samples using a TaqMan-based genotyping assay, and collateral circulation was assessed by the Rentrop method. Multivariate logistic regression models adjusted by clinically relevant variables to estimate odds ratios were used to examine associations of PLAU P141L allelic variants and genotypes with collateral circulation.
RESULTS: Patients with poor collateral circulation (Rentrop 0-1; n = 547) showed a higher frequency of the TT genotype than those with good collateral circulation (Rentrop 2-3; n = 129; P = .020). The T allele variant was also more common in patients with poor collateral circulation (P = .006). The odds ratio of having poorly developed collaterals in patients bearing the T allele (adjusted for clinically relevant variables) was statistically significant under the dominant model (odds ratio = 1.83 [95% confidence interval, 1.16-2.90]; P = .010) and the additive model (odds ratio = 1.73 [95% confidence interval, 1.14-2.62]; P = .009).
CONCLUSIONS: An association was found between coronary collateral circulation and the PLAU P141L polymorphism. Patients with the 141L variant are at greater risk of developing poor coronary collateral circulation.
Copyright © 2013 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.

Entities:  

Keywords:  Activador del plasminógeno; Association study; Circulación colateral; Collateral circulation; Estudio de asociación; Plasminogen activator; Polimorfismo rs2227564; rs2227564 polymorphism

Mesh:

Substances:

Year:  2014        PMID: 24952395     DOI: 10.1016/j.rec.2013.11.022

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  4 in total

1.  Genetic association study of coronary collateral circulation in patients with coronary artery disease using 22 single nucleotide polymorphisms corresponding to 10 genes involved in postischemic neovascularization.

Authors:  Joan Duran; Pilar Sánchez Olavarría; Marina Mola; Víctor Götzens; Julio Carballo; Eva Martín Pelegrina; Màrius Petit; Omar Abdul-Jawad; Imanol Otaegui; Bruno García del Blanco; David García-Dorado; Josep Reig; Alex Cordero; Josep Maria de Anta
Journal:  BMC Cardiovasc Disord       Date:  2015-05-12       Impact factor: 2.298

2.  Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor.

Authors:  Joseph Dowsett; Egil Ferkingstad; Line Jee Hartmann Rasmussen; Lise Wegner Thørner; Magnús K Magnússon; Karen Sugden; Gudmar Thorleifsson; Mike Frigge; Kristoffer Sølvsten Burgdorf; Sisse Rye Ostrowski; Erik Sørensen; Christian Erikstrup; Ole Birger Pedersen; Thomas Folkmann Hansen; Karina Banasik; Søren Brunak; Vinicius Tragante; Sigrun Helga Lund; Lilja Stefansdottir; Bjarni Gunnarson; Richie Poulton; Louise Arseneault; Avshalom Caspi; Terrie E Moffitt; Daníel Gudbjartsson; Jesper Eugen-Olsen; Hreinn Stefánsson; Kári Stefánsson; Henrik Ullum
Journal:  Commun Biol       Date:  2021-06-02

3.  Challenges imposed by minor reference alleles on the identification and reporting of clinical variants from exome data.

Authors:  Mahmoud Koko; Mohammed O E Abdallah; Mutaz Amin; Muntaser Ibrahim
Journal:  BMC Genomics       Date:  2018-01-15       Impact factor: 3.969

4.  Overexpression of PSMC2 promotes the tumorigenesis and development of human breast cancer via regulating plasminogen activator urokinase (PLAU).

Authors:  Yanyan Wang; Mingzhi Zhu; Jingruo Li; Youyi Xiong; Jing Wang; Haihong Jing; Yuanting Gu
Journal:  Cell Death Dis       Date:  2021-07-09       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.